Abrysvo Unia Europejska - polski - EMA (European Medicines Agency)

abrysvo

pfizer europe ma eeig - respiratory syncytial virus, subgroup a, stabilized prefusion f protein / respiratory syncytial virus, subgroup b, stabilized prefusion f protein - infekcje wirusem oddechowym - szczepionki - abrysvo is indicated for:passive protection against lower respiratory tract disease caused by respiratory syncytial virus (rsv) in infants from birth through 6 months of age following maternal immunisation during pregnancy. zobacz rozdziały 4. 2 i 5. active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by rsv. stosowanie tej szczepionki powinno odbywać się zgodnie z oficjalnymi zaleceniami.

Arexvy Unia Europejska - polski - EMA (European Medicines Agency)

arexvy

glaxosmithkline biologicals s.a.  - respiratory syncytial virus recombinant glycoprotein f stabilised in the pre-fusion conformation (rsvpref3) produced in chinese hamster ovary (cho) cells by recombinant dna technology - infekcje wirusem oddechowym - szczepionki - arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (lrtd) caused by respiratory syncytial virus in adults 60 years of age and older. stosowanie tej szczepionki powinno odbywać się zgodnie z oficjalnymi zaleceniami.